– City of Hope to Evaluate PEDMARK® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest in Addressing the Burden of Hearing Loss Among Patients Receiving Cisplatin-Based Chemotherapy – Research Triangle Park, NC, December 9, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; […]
Category: Uncategorized
FENNEC PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM INVESTIGATOR-INITIATED CLINICAL STUDY OF PEDMARK® IN JAPAN TO REDUCE CISPLATIN-INDUCED HEARING LOSS
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) – – PEDMARK® Showed No Interference with Cisplatin Antitumor Activity as Evidenced by […]
FENNEC PHARMACEUTICALS TO PARTICIPATE IN PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE
RESEARCH TRIANGLE PARK, N.C., November 25, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET, which will be available via webcast. Webcast Detail: […]
FENNEC PHARMACEUTICALS ANNOUNCES COMPLETION OF FULL DEBT REDEMPTION
Research Triangle Park, NC, November 19, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES COMPLETION OF FULL DEBT REDEMPTION
FENNEC PHARMACEUTICALS ANNOUNCES CLOSING OF PRIVATE OFFERING OF COMMON SHARES IN CANADA
Research Triangle Park, NC, November 17, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proceeds of US$5,025,000. […]
FENNEC PHARMACEUTICALS ANNOUNCES CLOSING OF OFFERING OF COMMON SHARES
Research Triangle Park, NC, November 17, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters’ option to purchase additional common shares) at a public offering price […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES CLOSING OF OFFERING OF COMMON SHARES
FENNEC PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF COMMON SHARES
Research Triangle Park, NC, November 13, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten registered public offering of 4,666,667 common shares at a public offering price of $7.50 per share. In addition, Fennec has granted the underwriters a 30-day option to […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF COMMON SHARES
FENNEC PHARMACEUTICALS ANNOUNCES PRIVATE OFFERING OF COMMON SHARES IN CANADA
Research Triangle Park, NC, November 13, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES PRIVATE OFFERING OF COMMON SHARES IN CANADA
FENNEC PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
~ Q3 2025 Total Net Product Sales of $12.5 Million, 79% Year Over Year Growth ~ ~ Q3 2025 Positive Cash Flow from Operations, Cash Position Grew to $22 Million ~ ~ Japan Clinical Trial (STS-J01) Preliminary Results Expected in Q4 2025 ~ Research Triangle Park, NC, November 13, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), […]
FENNEC PHARMACEUTICALS ANNOUNCES PROPOSED OFFERING OF COMMON SHARES
Research Triangle Park, NC, November 13, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public offering. In addition, Fennec intends to grant the underwriters a 30-day option to purchase up to an […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES PROPOSED OFFERING OF COMMON SHARES